Italy seeks €1.2bn over 'illicit' Swiss drug deal
AFP - [email protected] •
29 May, 2014
Updated Thu 29 May 2014 08:24 CEST
Italy's health ministry is seeking €1.2 billion in compensation from Swiss pharma giants Novartis and
Roche for the manipulation of sales of a cheap drug used to treat eye problems, Italian media reported on Wednesday.
The ministry's move came after Italy's antitrust body fined the two firms €182.5 million over their "illicit deal to prevent the use of a very cheap drug, Avastin, in treating" sight problems.
The antitrust body said the two pharma giants had colluded with the aim of boosting the sales of a more expensive product, Lucentis. It also claimed that they steered health services and doctors away from Avastin by describing it as more dangerous.
Both Roche and Novartis market Lucentis as the best medicine for the eye disease known as macular degeneration.
Novartis has rejected the anti-competition accusations and has said it would appeal against the fine.
Don't miss a story about Italy - Join us on Facebook and Twitter.
Comments
See Also
The ministry's move came after Italy's antitrust body fined the two firms €182.5 million over their "illicit deal to prevent the use of a very cheap drug, Avastin, in treating" sight problems.
The antitrust body said the two pharma giants had colluded with the aim of boosting the sales of a more expensive product, Lucentis. It also claimed that they steered health services and doctors away from Avastin by describing it as more dangerous.
Both Roche and Novartis market Lucentis as the best medicine for the eye disease known as macular degeneration.
Novartis has rejected the anti-competition accusations and has said it would appeal against the fine.
Don't miss a story about Italy - Join us on Facebook and Twitter.
Join the conversation in our comments section below. Share your own views and experience and if you have a question or suggestion for our journalists then email us at [email protected].
Please keep comments civil, constructive and on topic – and make sure to read our terms of use before getting involved.
Please log in here to leave a comment.